CoChat
Sign Up
Cited by 161Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

Johnson, J. A., Simpson, S. H., Toth, E. L., Majumdar, S. R.·2005·Diabetic Medicine
DOI 10.1111/j.1464-5491.2005.01448.x
Open this paper in CoChat — free account

Abstract

AIM: Metformin therapy reduces microvascular complications in Type 2 diabetes; questions remain, however, regarding its impact on macrovascular events. This study examined metformin use in relation to risk of cardiovascular-related hospitalization and mortality. METHODS: We conducted a retrospective cohort analysis, using Saskatchewan Health administrative databases to identify new users of oral antidiabetic drugs. Subject groups were defined by medication use during 1991-1999: sulphonylurea monotherapy, metformin monotherapy, or combination therapy. Deaths and non-fatal hospitalizations recorded during the study period were identified as cardiovascular-related from ICD-9 codes. The main outcome was a composite of first non-fatal hospitalization or death. Standard multivariate techniques, including propensity scores, were used to adjust for potential confounding. Multivariate Cox proportional hazard models were used to examine the relationship between metformin use and the composite endpoint. RESULTS: Metformin monotherapy was associated with a lower risk of the composite endpoint (adjusted hazard ratio 0.81; 95% confidence interval 0.68, 0.97) compared with sulphonylurea monotherapy. Combination therapy with meformin and a sulphonylurea was associated with lower mortality, but had similar hospitalization rates, to sulphonylurea monotherapy. CONCLUSIONS: Metformin monotherapy was associated with a lower risk of cardiovascular-related morbidity and mortality, and combination metformin and sulphonylurea therapy was associated with a reduced risk of fatal cardiovascular events, when compared with sulphonylurea monotherapy.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01448.x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Tsuyuki RT, 1999, Nitroglycerin as an indicator for the presence of coronary heart disease, Can Pharmaceut J, 132, 32

Cited by

Sorted by citations

See all 161

Related

See all

Metadata

Authors
Johnson, J. A., Simpson, S. H., Toth, E. L., & Majumdar, S. R.
Affiliations
  • University of Alberta (CA)
  • Institute of Health Economics (CA)
Corresponding author
Johnson, J. A.
ORCID
Venue
Diabetic Medicine
Publisher
Wiley
Published
2005-03-21
Volume
22
Issue
4
Pages
497-502
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
DOI
10.1111/j.1464-5491.2005.01448.x
OpenAlex
W1994294400
Cited by
161
References
31
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 7 · 2017: 8 · 2016: 6 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 11
FWCI
6.42
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetic Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
metformin, type 2 diabetes, cardiovascular morbidity, cardiovascular mortality, macrovascular complications, cardiovascular hospitalization, oral antidiabetic drugs
MeSH terms
Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Drug Therapy, Combination, Epidemiologic Methods, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Saskatchewan, Sulfonylurea Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review